IRADIMED CORP (IRMD) Stock Fundamental Analysis

NASDAQ:IRMD • US46266A1097

103.53 USD
+1.11 (+1.08%)
At close: Feb 27, 2026
103.53 USD
0 (0%)
After Hours: 2/27/2026, 8:11:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall IRMD gets a fundamental rating of 7 out of 10. We evaluated IRMD against 185 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues. IRMD is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make IRMD a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year IRMD was profitable.
  • IRMD had a positive operating cash flow in the past year.
  • In the past 5 years IRMD has always been profitable.
  • Of the past 5 years IRMD 4 years had a positive operating cash flow.
IRMD Yearly Net Income VS EBIT VS OCF VS FCFIRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M 15M 20M 25M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 18.47%, IRMD belongs to the top of the industry, outperforming 99.46% of the companies in the same industry.
  • The Return On Equity of IRMD (21.54%) is better than 95.14% of its industry peers.
  • With an excellent Return On Invested Capital value of 19.32%, IRMD belongs to the best of the industry, outperforming 97.30% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 8.75%.
Industry RankSector Rank
ROA 18.47%
ROE 21.54%
ROIC 19.32%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
IRMD Yearly ROA, ROE, ROICIRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

1.3 Margins

  • The Profit Margin of IRMD (26.31%) is better than 96.76% of its industry peers.
  • IRMD's Profit Margin has improved in the last couple of years.
  • IRMD's Operating Margin of 30.87% is amongst the best of the industry. IRMD outperforms 98.38% of its industry peers.
  • IRMD's Operating Margin has improved in the last couple of years.
  • IRMD has a Gross Margin of 77.07%. This is amongst the best in the industry. IRMD outperforms 89.73% of its industry peers.
  • In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
Industry RankSector Rank
OM 30.87%
PM (TTM) 26.31%
GM 77.07%
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
IRMD Yearly Profit, Operating, Gross MarginsIRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
  • IRMD has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IRMD has been increased compared to 5 years ago.
  • There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRMD Yearly Shares OutstandingIRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
IRMD Yearly Total Debt VS Total AssetsIRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 51.25 indicates that IRMD is not in any danger for bankruptcy at the moment.
  • IRMD has a Altman-Z score of 51.25. This is amongst the best in the industry. IRMD outperforms 99.46% of its industry peers.
  • IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 51.25
ROIC/WACC1.96
WACC9.88%
IRMD Yearly LT Debt VS Equity VS FCFIRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.3 Liquidity

  • IRMD has a Current Ratio of 6.64. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
  • IRMD's Current ratio of 6.64 is amongst the best of the industry. IRMD outperforms 84.32% of its industry peers.
  • A Quick Ratio of 5.72 indicates that IRMD has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 5.72, IRMD belongs to the best of the industry, outperforming 84.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.64
Quick Ratio 5.72
IRMD Yearly Current Assets VS Current LiabilitesIRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 16.36% over the past year.
  • IRMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 36.18% yearly.
  • Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 14.43% in the last year.
  • The Revenue has been growing by 21.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%

3.2 Future

  • Based on estimates for the next years, IRMD will show a small growth in Earnings Per Share. The EPS will grow by 5.87% on average per year.
  • The Revenue is expected to grow by 10.59% on average over the next years. This is quite good.
EPS Next Y12.63%
EPS Next 2Y5.87%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRMD Yearly Revenue VS EstimatesIRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
IRMD Yearly EPS VS EstimatesIRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 53.92, IRMD can be considered very expensive at the moment.
  • 68.11% of the companies in the same industry are more expensive than IRMD, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.10. IRMD is valued rather expensively when compared to this.
  • With a Price/Forward Earnings ratio of 47.88, IRMD can be considered very expensive at the moment.
  • 67.03% of the companies in the same industry are more expensive than IRMD, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (28.06), we can say IRMD is valued expensively.
Industry RankSector Rank
PE 53.92
Fwd PE 47.88
IRMD Price Earnings VS Forward Price EarningsIRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than 64.86% of the companies in the same industry.
  • 69.19% of the companies in the same industry are more expensive than IRMD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 94.4
EV/EBITDA 48.79
IRMD Per share dataIRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)4.27
PEG (5Y)1.49
EPS Next 2Y5.87%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • IRMD has a yearly dividend return of 0.69%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.20, IRMD pays a better dividend. On top of this IRMD pays more dividend than 91.35% of the companies listed in the same industry.
  • With a Dividend Yield of 0.69, IRMD pays less dividend than the S&P500 average, which is at 1.83.
Industry RankSector Rank
Dividend Yield 0.69%

5.2 History

  • IRMD has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
IRMD Yearly Dividends per shareIRMD Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • 39.59% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.59%
EPS Next 2Y5.87%
EPS Next 3YN/A
IRMD Yearly Income VS Free CF VS DividendIRMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
IRMD Dividend Payout.IRMD Dividend Payout, showing the Payout Ratio.IRMD Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IRADIMED CORP

NASDAQ:IRMD (2/27/2026, 8:11:42 PM)

After market: 103.53 0 (0%)

103.53

+1.11 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-04
Inst Owners57.86%
Inst Owner Change3.26%
Ins Owners36.79%
Ins Owner Change-0.61%
Market Cap1.32B
Revenue(TTM)83.81M
Net Income(TTM)21.18M
Analysts82.5
Price Target122.4 (18.23%)
Short Float %5.94%
Short Ratio6.09
Dividend
Industry RankSector Rank
Dividend Yield 0.69%
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.59%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-23
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.85%
Min EPS beat(2)1.27%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)2.54%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.04%
EPS beat(16)14
Avg EPS beat(16)9.77%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.01%
Max Revenue beat(2)1.41%
Revenue beat(4)2
Avg Revenue beat(4)-0.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)1.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)21.21%
PT rev (3m)21.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.02%
Revenue NY rev (3m)1.99%
Valuation
Industry RankSector Rank
PE 53.92
Fwd PE 47.88
P/S 16.36
P/FCF 94.4
P/OCF 52.65
P/B 13.39
P/tB 13.87
EV/EBITDA 48.79
EPS(TTM)1.92
EY1.85%
EPS(NY)2.16
Fwd EY2.09%
FCF(TTM)1.1
FCFY1.06%
OCF(TTM)1.97
OCFY1.9%
SpS6.33
BVpS7.73
TBVpS7.47
PEG (NY)4.27
PEG (5Y)1.49
Graham Number18.28
Profitability
Industry RankSector Rank
ROA 18.47%
ROE 21.54%
ROCE 24.38%
ROIC 19.32%
ROICexc 43.38%
ROICexgc 46.87%
OM 30.87%
PM (TTM) 26.31%
GM 77.07%
FCFM 17.33%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
ROICexc(3y)50.3%
ROICexc(5y)54.7%
ROICexgc(3y)53.86%
ROICexgc(5y)59.46%
ROCE(3y)25.8%
ROCE(5y)22.12%
ROICexgc growth 3Y-15.8%
ROICexgc growth 5YN/A
ROICexc growth 3Y-12.49%
ROICexc growth 5YN/A
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1128.47%
Cap/Sales 13.74%
Interest Coverage 250
Cash Conversion 96.82%
Profit Quality 65.85%
Current Ratio 6.64
Quick Ratio 5.72
Altman-Z 51.25
F-Score4
WACC9.88%
ROIC/WACC1.96
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
EPS Next Y12.63%
EPS Next 2Y5.87%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.55%
EBIT growth 3Y18.71%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.2%
OCF growth 3YN/A
OCF growth 5YN/A

IRADIMED CORP / IRMD FAQ

Can you provide the ChartMill fundamental rating for IRADIMED CORP?

ChartMill assigns a fundamental rating of 7 / 10 to IRMD.


Can you provide the valuation status for IRADIMED CORP?

ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.


Can you provide the profitability details for IRADIMED CORP?

IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.


What are the PE and PB ratios of IRADIMED CORP (IRMD) stock?

The Price/Earnings (PE) ratio for IRADIMED CORP (IRMD) is 53.92 and the Price/Book (PB) ratio is 13.39.


Can you provide the financial health for IRMD stock?

The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.